# A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

> **NCT00457392** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 960 (actual)

## Conditions studied

- Carcinoma, Non-Small Cell Lung

## Interventions

- **DRUG:** erlotinib
- **DRUG:** sunitinib
- **DRUG:** erlotinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00457392
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-07
- **Final completion:** 2012-12
- **Target enrollment:** 960 (ACTUAL)
- **Last updated:** 2013-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00457392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00457392, "A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00457392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*